ClinicalTrials.gg
CompletedNCT04299243Updated Mar 6, 2020

Clinical Trial Protocol for Safety and Efficacy of Soft Contact Lens

An interventional study of Contact Lenses in Myopia, sponsored by Menicon Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-03-06.

Sponsored by Menicon Co., Ltd. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 2 months after the study started (first participant enrolled Nov 2018, registered Feb 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
148
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 222 studies in Myopia with a site in China — 80 open to participants now, 102 under way, 4 of them phase 3. Myopia · China.

Enrollment
79th of 155
148 · median 150
Started
2018
with 12 others
No phase
136 of 222
53 open now
Registered
48th of 222
by date

Among the 222 studies in Myopia with a site in China, this one is the 79th largest by enrollment of the 155 interventional ones that give a count, is one of 13 that started in 2018, is one of 136 with no phase, and was the 48th registered.

Myopia

1,166 studies on the registry are indexed under Myopia; 228 are open to participants now.

Browse Myopia studies →

Open to participants now

80 of the 222 studies in Myopia with a site in China are open now. Recruiting first, the newest first:

75 more — sign in →

All 80 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 124 Myopia studies recruiting now, 20 (16%) set no upper age limit and 103 (83%) stop at 75 or younger; 85 take children under 18; 53 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 222 studies in Myopia with a site in China, or all of them as a file.
02

Study summary

This project is a multi-center, randomized, parallel-controlled, non-inferior clinical trial of soft contact lenses.

Read the detailed description

The test product is the Soft Contact Lens (model: Spherical Lens), and the control product is a commercially available soft contact lens (model: SiHy Daily). The number of enrolled subjects is 148, and clinical observation is performed for 3 months.

03

Conditions studied

  • Myopia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female with age of 18 to 45
  • Spherical power: -0.25 to -10.00D
  • Cylinder power ≤0.75D and Sph.P:Cyl.P≥3:1, or 1.00D≤ cylinder power ≤1.50D and Sph.P:Cyl.P ≥4:1;
  • Both eyes are ametropia, and there is no case where the investigator believes that the soft contact lens cannot be worn;

    : The case of wearing a soft contact lens as referred to in this trial is: i) No eyelid abnormalities or infections; ii) No slit lamp findings iii) No other active eye diseases.

  • BCVA of the left and right eye subjective refraction is greater than or equal to 5.0.

Exclusion criteria

Exclusion Criteria:

  • Need to use therapeutic ophthalmic drugs, including antibiotics, hormones and compound ophthalmic drugs containing hormones
  • Dry eye syndrome
  • Any systemic disease to contact lenses or disease medications can affect the wearing of contact lenses
  • Wearing a hard contact lens in the past 6 weeks
  • Tear film break-up time is less than or equal to 5s
  • Allergic to contact lenses and/or contact lenses
  • Keratoconus or other irregular corneal patients
  • Soft hydrophilic contact lens wearers are affected by long-term special conditions such as dryness, severe dust or volatile chemicals
  • Pregnant, lactating or plan to be pregnant
  • Only one eye meets the requirements for enrollment
  • Participating in other clinical trials or less than ten days after the end of a soft contact lens clinical trial
  • Less than three months after the end of a drug clinical trial
  • Determined by the investigator that could not be enrolled
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
148 participants (actual)

Study arms

  • Experimental
    Spherical Lens

    Randomized to Spherical Lens worn in a daily disposable mode

    Device: Contact Lenses

  • Active comparator
    SiHy Daily

    Randomized to SiHy Daily worn in a daily disposable mode

    Device: Contact Lenses

Interventions

  • DeviceContact Lenses

    Contact lenses for vision correction

06

What researchers measure

Primary outcomes

  1. The ratio of corrected visual acuity of left and right eyes is ≥5.0

    The standard logarithmic visual acuity chart consistent with the guiding principle is adopted in this scheme. - Success criteria: If the lower limit of 95% CI of the evaluated rate of corrected for visual acuity for both eyes ≥ 5.0 at 1 week visit is ≥-10%, the primary endpoint of the two groups is non-inferior.

    Time frame: 1 week

  2. The occurrence of adverse events

    Compare the number of adverse events and serious adverse events, the number of cases and the incidence rate; list the number and cases of adverse events; describe the adverse events that are related to the investigational products.

    Time frame: 3 month

Secondary outcomes

  1. BCVA (spectacles) and BCVA (CL)

    BCVA (spectacles and CL) of both eyes are compared at baseline and at each follow-up.

    Time frame: 1 week, 1 month, 3 months

07

Study locations

1 site
  • Tianjin Eye Hospital
    Tianjin, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in May 2019, 5 months.

Of 236 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's 5 months is below that.

Counting every sponsor, half of 438 studies reached it within 14 months; a quarter within 3 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2020
First posted
Mar 6, 2020
StartActual
Nov 25, 2018
Primary completionActual
May 15, 2019
CompletionActual
Jun 1, 2019
Last update
Mar 6, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04299243
Lead sponsor
Menicon Co., Ltd.
Responsible party
Sponsor
First posted
Mar 6, 2020
Start date
Nov 25, 2018
Primary completion
May 15, 2019
Completion
Jun 1, 2019
Last update
Mar 6, 2020

Study contacts

Li Lihua, MD
principal investigator · Tianjin Eye Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion